Serum Institute Of India Agreement

Ministry of Foreign Affairs, Govt. india, in close collaboration with the Ministry of Health has purchased a delivery of 30,000 doses of measles/rubella vaccines from the Serum Institute of India in DerRuhe for an emergency health crisis in the Maldives. Read more: “The signing of the manufacturing contract with Novavax for NVX-CoV2373 is another major milestone for both companies, which will further strengthen our existing relationship. SIIPL`s expertise in the scale and production of NVX-CoV2373 will help ensure the supply of this most needed vaccine,” said Adar Poonawalla, Chief Executive Officer of the Serum Institute of India. This brings to 200 million doses the total number of doses of vaccines that will be covered by the partnership between SII, Gavi and the Gates Foundation, following an initial agreement of up to 100 million doses in August. Oxford University, in partnership with AstraZeneca, has taken the next steps in its commitment to broad and equitable global access to Oxford`s COVID 19 vaccine, after entering into pioneering agreements with the Coalition for Epidemic Preparedness Innovation (CEPI), Gavi the Vaccine Alliance and the Serum Institute of India (SII). Read more – Oxford University As part of an agreement with the American pharmaceutical developer, the Serum Institute will develop two billion doses of the Novavax candidate each year. The drug manufacturer will also produce the antigen component of the vaccine. Novavax is currently conducting late trials in the UK and expects to report by the first quarter of 2021. “Today`s agreement with the Serum Institute reinforces Novavax`s commitment to fair global delivery of our COVID 19 vaccine. Through this agreement, we have established a global supply chain that includes recently acquired Praha vaccines and partnerships with leading manufacturers of biologists, and allows production on three continents,” said Stanley C. Erck, Executive Chairman of Novavax.

“We continue to work urgently on the development of our vaccine, which is currently testing Phase 2 clinical trials and for which we expect to launch Phase 3 efficacy studies worldwide in the coming weeks. Dr.